FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2010/091/000301 [Registered on: 27/04/2010]
Last Modified On: 15/03/2013
Post Graduate Thesis   
Type of Trial  Interventional 
Type of Study
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A first-in-man clinical trial to evaluate the safety and immunogenicity of different doses of a malaria Vaccine (JAIVAC-1) in healthy Indian Male Subjects between 18 to 45 years of age 
Scientific Title of Study   A Phase I, Randomised, Controlled, Dose-Escalating, Single-Blind Clinical Trial to Evaluate the Safety and Immunogenicity of JAIVAC-1 Vaccine (PfMSP-119 and PfF2) formulated with Montanide ISA 720 in Healthy Indian Male Subjects between 18 to 45 Years of Age 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
JAIVAC-1_1_09  Protocol Number 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
Name  Dr Preethi Shivyogi 
Address  Lotus Labs Pvt. Ltd.
100 ft. road, 3rd Block Koramangalam
Phone  91-80-22370912  
Fax  91-80-22370911  
Email  preethishivyogi@lotuslabs.com  
Details of Contact Person
Scientific Query

Name  Manali Rane 
Address  DiagnoSearch Life Sciences Pvt. Ltd.
Dosti Pinnacle, Plot No. E-7, Road No. 22, Wagle Industrial Estate,
400 604
Phone  022-67776300  
Fax  022-66754090  
Email  manali.rane@diagnosearch.com  
Details of Contact Person
Public Query

Name  Dr Chetan ChitnisProf Virendra Chauhan 
Address  1)Malaria Vaccine Development Program (MVDP) 2)International Center for Genetic Engineering and Biotechnology(ICGEB)
1)The Capital Court,Transcend Business Centre Olof Palme Marg 2)Aruna Asaf Ali Road
New Delhi
Phone  011-26742895  
Fax  011-26742316  
Email  cchitnis@gmail.com  
Source of Monetary or Material Support  
European Vaccine Initiative UniversitätsKlinikum Heidelberg Im Neuenheimer Feld ? 307 69120 Heidelberg - Germany  
Primary Sponsor
Name  International Center for Genetic Engineering and Biotechnology MVDP 
Address  Aruna Asaf Ali Road, New Delhi-110067,India The Capital Court,Transcend Business Centre Olof Palme Marg, New Delhi-110067 India  
Type of Sponsor  Research institution 
Details of Secondary Sponsor  
Name  Address 
European Vaccine Initiative UniversitätsKlinikum Heidelberg Im Neuenheimer Feld ? 307 69120 Heidelberg - Germany    
Countries of Recruitment     India  
Sites of Study
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr James John  Lotus Lab Pvt. Ltd  100 feet road,3rd Block, Koramangala-560034
Details of Ethics Committee
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC Consultants  Approved 
Regulatory Clearance Status from DCGI
Health Condition / Problems Studied  
Health Type  Condition 
Patients  Testing Plasmodium falciparum Malaria Vaccine,  
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Hepatitis B vaccine  Details provided in "Brief Summary" 
Intervention  JAIVAC-1 Vaccine (PfMSP-119 and PfF2) formulated with Montanide ISA 720  Deatils provided in "Brief Summary" 
Inclusion Criteria
Age From  18.00 Year(s)
Age To  45.00 Year(s)
Gender  Male 
Details  1. Male subject aged 18 to 45 years (both inclusive)
2. Subject with general good health based on the medical history
and clinical examination
3. Subject must be willing to sign the Informed Consent Form
4. Subject must be reachable by phone during the entire study
period (12 months)
5. Subject must be capable and willing to complete and return
diary cards and to attend all follow-up visits
6. Male subject must agree to use one of the following medicallyacceptable
birth control measures throughout the duration of
the study (birth control counselling and measures will be
provided by sites as required)
? Double barrier method (e.g. condom with spermicidal
jelly) used for the entire study period
? Should be Surgically sterile (vasectomy) 
Details  1. Subject with evidence of IgG antibodies against PfMSP-119 and
PfF2 as measured by ELISA
2. Subject with prior history of immunisation with Hepatitis B vaccine
3. Subject with known history of malaria
4. Subject with history of allergic reactions, hypersensitivity or
anaphylaxis to any of the components of the study vaccines
(JAIVAC-1 ? Montanide ISA 720 malaria vaccine or Hepatitis B
vaccine) (including adjuvant or peptide) or with history of serious
allergic reactions to any substance, requiring hospitalisation or
emergency medical care
5. Subject with previous vaccination with any other malaria candidate
6. Subject with use of an investigational or non-registered drug or
vaccine other than the study vaccines within three (3) months
preceding the first study vaccination, or planned use during the
entire clinical trial period
7. Subject, who receives any vaccination or gamma globulin during
the three-month period prior to the first vaccination
8. Subject with chronic administration (defined as more than 14 days)
of immuno-suppressants or other immune-modifying drugs within
six months prior to the first vaccination. This includes any dose
level of oral steroids or inhaled steroids, but not topical steroids
9. Subjects will be excluded if AST 40 IU/L, ALT 41 IU/L, γ
GT 71 IU/L, Total Bilirubin 1.2 mg/ dL, Indirect Bilirubin
1.2 mg/ dL, Direct Bilirubin 0.4 mg/dL, Serum Creatinine 1.2
mg/ dL(Appendix B and B-1).
10. Subjects will be excluded in case of out of range values for the
following parameters: Hemoglobin 13 to 18 g/ dL, RBC count 4.0
to 7.0 × 10E6/µL TLC 4.0 to 11.0 × 10E3/µL, platelet count 150
to 500 × 10E3/µL, Neutrophils 40 to 75 % or Eosinophils 10
%, Sodium 136 to 145 mEq/L, Potassium 3.5 to 5.1 mEq/L,
Random Blood Glucose 45 to 130 mg/dl and Alkaline Phosphatase
40 to 129 U/L (Appendix B and B-1)
11. Subjects with other clinically significant abnormal laboratory values
based on the normal reference range (Refer Appendix B and B1)
apart from the laboratory parameters listed above. 
Method of Generating Random Sequence   Permuted block randomization, fixed 
Method of Concealment   Pre-numbered or coded identical Containers 
Blinding/Masking   Participant Blinded 
Primary Outcome  
Outcome  TimePoints 
The safety profile will be assessed on the basis of the following criteria �� Immediate reactogenicity (any event occurring within the first three (3) hours after each vaccination, with emphasis on allergic reactions) �� Local and systemic reactogenicity (any event occurring from three (3) hours post vaccination on Day 0 till Day 14 after each dose) �� Any unsolicited adverse events 28 days after each vaccination �� Any Serious Adverse Event (SAE) occurring from the first dose of vaccine till the last follow-up visit. �� Biological safety, 28 days after each vaccination, in reference with the baseline before the first dose, by measuring the following parameters: ? Haematology: RBC Count, Haemoglobin*, Haematocrit/Packed Cell Volume (PCV), MCV (Mean Corpuscular Volume), MCH (Mean Corpuscular Haemoglobin), MCHC (Mean Corpuscular Haemoglobin Concentration) on Days -14, 28, 56, 180, 208, 365 ? Platelet Count and Total Leukocyte Count (TLC) along with Differential Leukocyte Count (DLC) on Days -14, 28, 56, 180, 208, 365. *If the haemoglobin drops below 13 gm/dL, then a direct Coomb?s test and a peripheral blood smear/film will be prepared and examined for evidence of possible haemolysis ? Serum Chemistry: Potassium, Sodium, AST, ALT, Direct, Indirect and Total Bilirubin, Alkaline Phosphatase, Gamma Glutamyl Transpeptidase (γGT), Creatinine, and Random blood glucose on Days -14, 28, 56, 180, 208, 365 The Investigator will be responsible for causality assessment i.e. assessment of the relationship of the AE to either of the assigned the study vaccines, using the following definitions: related or not related.  NA 
Secondary Outcome  
Outcome  TimePoints 
? The humoral response to the candidate vaccine antigen will be assessed (quantitative assessment) by measuring the level of IgG antibodies developed against PfMSP-119 and PfF2 by ELISA on Days 0, 28, 56, 180, 208 and 365 ? The humoral response to the candidate vaccine antigen will be assessed (qualitative assessment) to verify the ability of the IgG antibodies developed against PfMSP-119 and PfF2 to recognise the native proteins, namely, PfMSP1 and EBA175 in late stage P. falciparum schizonts and merozoites by IFA on Days 0, 28, 56, 180, 208 and 365.   NA 
Target Sample Size
Total Sample Size="45"
Sample Size from India="45" 
Final Enrollment numbers achieved (Total)= ""
Final Enrollment numbers achieved (India)="" 
Phase of Trial   Phase 1 
Date of First Enrollment (India)
Date of Study Completion (India) Date Missing 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="2"
Recruitment Status of Trial (Global)
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details    
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary   This Phase I, first in man study is designed as a randomized, controlled, single-blind and dose-escalating clinical study for the assessment of the safety and immunogenicity of JAIVAC-1 malaria vaccine (PfMSP-119 and PfF2) formulated with Montanide ISA 720 as an adjuvant in healthy Indian male subjects between 18 to 45 years of age. The study involves testing of three (3) different dosages of JAIVAC-1 malaria vaccine in three different dosage cohorts. Hepatitis B vaccine will serve as an active control. Each Cohort will have 15 subjects. The randomization schedule will be 2:1, i.e. 10 subjects will receive the investigational vaccine and 5 subjects will be administered hepatitis- B, the control vaccine. Thus, in total in this study, 30 subjects will receive JAIVAC-1―Montanide ISA720 (10 subjects at each dosage cohort) and 15 subjects will receive control vaccine. Both the study vaccines will be administered via intramuscular route and shall have a 3-dose schedule on Days 0, 28 and 180. In the first Cohort subjects will receive 0.1 ml of investigational vaccine. If found to be safe and well tolerated second cohort will receive 0.25 ml of investigational vaccine and finally Cohort 3 will receive 0.5 ml of investigational vaccine. Each cohort will be staggered into sub-cohorts such that the subjects in each cohort will be enrolled over a three-day period. The first three (3) subjects of the first dose (Cohort 1) will be kept under observation for 24 hrs following vaccination. The decision of the 24-hour housing for the remaining subjects will be jointly taken by the Principal Investigator and Medical and Safety Monitor, DLS.